Clinical Trial Update: Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study [Phase 3]

View source ↗

Summary

Phase 3 RELIEVE-02 trial evaluating neoadjuvant chemoradiotherapy with or without tislelizumab for resectable ultra-low rectal cancer; currently not yet recruit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer

Drugs mentioned

• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Rectal Cancer | Phase 3 | Status: NOT_YET_RECRUITING